Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

President Donald Trump told Fox News host Sean Hannity that the pal who starred in the "fat shot" story was "very worried" ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Key Takeaways More U.S. teens are getting weight-loss surgeryThe procedures increased 15% between 2021 and 2023At the same ...

Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...

Studies have shown that GLP-1s reduce inflammation in the brain and regulate anxiety as well as depression. When insurance ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he ...